Skip to main content
logo
Hologic, Inc. (HOLX)
Apr 7, 2026 - HOLX was delisted (reason: acquired by Blackstone and TPG)
76.01
0.00 (0.00%)
Inactive · Last trade price on Apr 6, 2026

Revenue Breakdown

Millions USD. Fiscal year is Oct - Sep.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013
Period Ending
Dec '25 Sep '25 Sep '24 Sep '23 Sep '22 Sep '21 Sep '20 Sep '19 Sep '18 Sep '17 Sep '16 Sep '15 Sep '14 Sep '13
Diagnostics Revenue
1.82B1.83B1.78B
Diagnostics Revenue Growth
-0.34%2.54%-5.22%
Breast Health Revenue
1.49B1.48B1.52B
Breast Health Revenue Growth
0.46%-2.55%6.30%
GYN Surgical Revenue
694.20M679.80M641.30M
GYN Surgical Revenue Growth
2.12%6.00%6.14%
Skeletal Health Revenue
120.20M109.40M84.10M
Skeletal Health Revenue Growth
9.87%30.08%-25.84%
Revenue (Other)
100.00K--
Revenue (Total)
4.13B4.10B4.03B
Revenue (Total) Growth
0.63%1.74%-0.00%

Revenue by Geography

Millions USD. Fiscal year is Oct - Sep.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013
Period Ending
Dec '25 Sep '25 Sep '24 Sep '23 Sep '22 Sep '21 Sep '20 Sep '19 Sep '18 Sep '17 Sep '16 Sep '15 Sep '14 Sep '13
United States Revenue
3.06B3.05B3.02B
United States Revenue Growth
0.51%0.79%-1.11%
Europe Revenue
603.70M591.00M532.70M
Europe Revenue Growth
2.15%10.94%2.38%
Asia-Pacific Revenue
240.30M243.30M259.60M
Asia-Pacific Revenue Growth
-1.23%-6.28%1.52%
Rest of World Revenue
219.10M218.30M213.90M
Rest of World Revenue Growth
0.37%2.06%8.91%
Revenue (Total)
4.13B4.10B4.03B
Revenue (Total) Growth
0.63%1.74%-0.00%

Revenue Breakdown 2

Millions USD. Fiscal year is Oct - Sep.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013
Period Ending
Dec '25 Sep '25 Sep '24 Sep '23 Sep '22 Sep '21 Sep '20 Sep '19 Sep '18 Sep '17 Sep '16 Sep '15 Sep '14 Sep '13
Disposables Revenue
2.60B2.62B2.49B
Disposables Revenue Growth
-0.74%5.12%-1.94%
Capital Equipment, Components and Software Revenue
671.40M638.40M764.90M
Capital Equipment, Components and Software Revenue Growth
5.17%-16.54%3.29%
Service Revenue
837.90M825.50M758.20M
Service Revenue Growth
1.50%8.88%3.79%
Other Sources Revenue
19.00M18.90M17.00M
Other Sources Revenue Growth
0.53%11.18%-15.00%
Revenue (Total)
4.13B4.10B4.03B
Revenue (Total) Growth
0.63%1.74%-0.00%

EBIT

Millions USD. Fiscal year is Oct - Sep.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013
Period Ending
Dec '25 Sep '25 Sep '24 Sep '23 Sep '22 Sep '21 Sep '20 Sep '19 Sep '18 Sep '17 Sep '16 Sep '15 Sep '14 Sep '13
Diagnostics Income from Operations
-599.90M509.50M
Diagnostics Income from Operations Growth
-17.74%-14.77%
Breast Health Income from Operations
-436.80M476.70M
Breast Health Income from Operations Growth
--8.37%21.14%
GYN Surgical Income from Operations
-204.60M224.50M
GYN Surgical Income from Operations Growth
--8.86%10.54%
Skeletal Health Income from Operations
--3.70M-500.00K
Operating Income (Total)
721.50M714.30M882.60M
Operating Income (Total) Growth
1.01%-19.07%32.05%

EBIT 2

Millions USD. Fiscal year is Oct - Sep.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013
Period Ending
Dec '25 Sep '25 Sep '24 Sep '23 Sep '22 Sep '21 Sep '20 Sep '19 Sep '18 Sep '17 Sep '16 Sep '15 Sep '14 Sep '13
Diagnostics Operating Income (Pre-Q4 2025 Reporting)
--303.10M
Diagnostics Operating Income (Pre-Q4 2025 Reporting) Growth
--56.32%
Breast Health Operating Income (Pre-Q4 2025 Reporting)
--394.50M
Breast Health Operating Income (Pre-Q4 2025 Reporting) Growth
--44.51%
GYN Surgical Operating Income (Pre-Q4 2025 Reporting)
--185.50M
GYN Surgical Operating Income (Pre-Q4 2025 Reporting) Growth
---1.80%
Skeletal Health Operating Income (Pre-Q4 2025 Reporting)
---500.00K
Operating Income (Total)
721.50M714.30M882.60M
Operating Income (Total) Growth
1.01%-19.07%32.05%

Capital Expenditures

Millions USD. Fiscal year is Oct - Sep.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013
Period Ending
Dec '25 Sep '25 Sep '24 Sep '23 Sep '22 Sep '21 Sep '20 Sep '19 Sep '18 Sep '17 Sep '16 Sep '15 Sep '14 Sep '13
Diagnostics Capital Expenditures
92.60M86.70M80.20M
Diagnostics Capital Expenditures Growth
6.80%8.11%-5.87%
Breast Health Capital Expenditures
16.60M19.90M30.90M
Breast Health Capital Expenditures Growth
-16.58%-35.60%-24.82%
GYN Surgical Capital Expenditures
26.30M25.10M16.60M
GYN Surgical Capital Expenditures Growth
4.78%51.20%-2.35%
Skeletal Health Capital Expenditures
-400.00K1.40M
Skeletal Health Capital Expenditures Growth
--71.43%75.00%
Corporate Capital Expenditures
4.60M4.90M1.10M
Corporate Capital Expenditures Growth
-6.12%345.45%-81.97%
Updated Jan 29, 2026. Data Source: Fiscal.ai.